The antitumor effectiveness of cyclophosphamide (CTX) and other chemotherapeutics was shown to rely not only on direct cytotoxicity but also on immunogenic tumor cell death and systemic immunomodulatory mechanisms, including regulatory T cell (Treg) depletion, Th1 cell polarization, type I interferon (IFN) and proinflammatory cytokine production. IFN regulatory factor (IRF)-1 is a transcriptional regulator of IFNs and IFN-inducible genes, involved in the control of Th1 and Treg differentiation and in sterile inflammation. Aim of this study was to explore the role of IRF-1 in CTX-induced antitumor effects and related immune activities. This study shows for the first time that IRF-1 is important for the antitumor efficacy of CTX in mice. Moreover, experiments in tumor-bearing C57BL/6 mice showed that Irf1 gene expression in the spleen was transiently increased following CTX administration and correlated with the induction of Th1 cell expansion and of Il12p40 gene expression, which is the main Th1-driving cytokine. At the same time, CTX administration reduced both Foxp3 expression and Treg cell percentages. These effects were abrogated in Irf1 2/2 mice. Further experiments showed that the gene and/or protein expression of caspase-1, iNOS, IL-1b, IL-6 and CXCL10 and the levels of nitric oxide were modulated following CTX in an IRF-1-direct-orindirect-dependent manner, and highlighted the importance of caspase-1 in driving the sterile inflammatory response to CTX. Our data identify IRF-1 as important for the antitumor efficacy of CTX and for the regulation of many immunomodulatory activities of CTX, such as Th1 polarization, Treg depletion and inflammation.
Drug repositioning, namely, the renewed use of existing drugs, is a worthwhile strategy to offer more effective, cheaper and safer options to patients and relies for its development on the in-depth comprehension of the novel mechanisms of actions. 1 The therapeutic outcome of many chemotherapeutic agents was shown to rely on immunological mechanisms that cooperate with the drug direct cytotoxic effects. 2 Accumulating data show that cyclophosphamide (CTX)-mediated immunomodulation arises, paradoxically, from its dual cytotoxic effect on immune and tumor cells. [2] [3] [4] Similar to other immunogenic chemotherapies, the death of tumor cells triggered by CTX was reported to be accompanied by the emission of two of the three essential damage-associated molecular patterns (DAMPs) that characterize immunogenic cell death (ICD), such as the surface exposure of calreticulin and the release of HMGB1, 5 which eventually results in increased recruitment, tumor cell uptake and activation of dendritic cells (DCs). [5] [6] [7] At the systemic level, CTX can also modulate immune cell populations, including cells of the innate and adaptive immune response. The multiple immunomodulatory effects of CTX have been extensively exploited in combination with adoptive or active immunotherapy 3, [8] [9] [10] and the mechanisms proliferation, enhanced tumor infiltration by lymphocytes, B and T cell functional activation 12 and the production of a "cytokine storm." 12, 13 Important mechanisms by which CTX potentiates the efficacy of immunotherapy relate to CD4
1 T cells and include (i) the suppression of regulatory T-cells (Treg) 13, 17, 18 and of PD1 hi tumor-driven dysfunctional CD4 1 T cells, 19 (ii) the polarization of T helper (Th) cells toward the Th1 and Th17 phenotype 13, 20 and (iii) the differentiation of activated polyfunctional Th cells. 19 Through "omics" approaches, in mice and in cancer patients, we previously suggested that the immunomodulatory properties of CTX depend on the perception of danger associated with the proinflammatory death of leukocytes, introducing the concept of CTX-induced sterile inflammatory response (i.e., in the absence of infection). 4, 13, 16 Genomic and proteomic analyses of lymphoid organs, PBMC and plasma in mice 13 and cancer patients 16 showed that a single CTX treatment modulates the expression of about a thousand genes, related to DNA damage, stress, cell death, danger signal, pattern recognition receptors (PRRs), cytokines, chemokines and chemokine receptors. CTX also induces the release of several cytokines, chemokines and growth factors in the plasma, including inflammatory and Th1 polarizing cytokines, such as interleukin (IL)-12, IFN-g, IL-1b, IL-18, IL-8, CXCL9, CXCL10 and CCL2. Moreover, microarray analysis pointed out signatures related to apoptotic cell death (p53 pathway) and type I interferon (IFN) response. 16 Despite numerous studies, a single molecular mechanism that can explain so many apparently unrelated phenomena is still lacking.
Interferon regulatory factor 1 (IRF-1), originally identified as a transcriptional regulator of Ifnb gene expression, 21 regulates a number of target genes that play essential roles in physiological and pathological processes including many aspects of the innate and the adaptive immune response. 22, 23 In response to specific stimuli and in a cell type-and timespecific manner, [24] [25] [26] of IRF-1-regulated genes and functions are in common with genes (for example type I Ifn, Foxp3, Il15, Nos2, IL1b, Cxcl10, Oas1, p21, p53 and Puma) or cell subsets (Treg, Th1, NK) that were found to be modulated by CTX in our previous studies. 13, 16 To assess the involvement of IRF-1 in driving the antitumor efficacy and in regulating some important systemic immunomodulatory activities of CTX, we here evaluated the effects of CTX on (i) inhibition of Treg cells, (ii) expansion of Th1 lymphocytes and (iii) activation of the sterile inflammatory response in C57BL/6 wild-type (WT) versus Irf1 2/2 mice.
Material and Methods
Mice C57BL/6 mice were obtained from Charles River Breeding Laboratories (Calco, Italy). IRF-1 knockout (B6.129S2 -Irf1 ) mice were obtained from Jackson Laboratory (Bar Harbor, ME). All mice were housed in a pathogen-free facility and treated in accordance with the European Community guidelines.
Tumor cells and in vivo treatments
The mouse RBL-5 cells (Rauscher virus lymphoma cell line) were kindly provided by Dr J. P. Levy in 1987. Cells were expanded for a few passages and aliquots were frozen in liquid nitrogen. From each aliquot of parental stock, we generated a second batch of aliquoted and frozen cells that were What's new? Chemotherapy drugs such as cyclophosphamide (CTX) affect the expression of hundreds of genes; however, the molecular mechanisms that regulate these pleiotropic effects are not well understood. In this study, the authors found that interferon regulatory factor (IRF)-1 plays a crucial role in governing the antitumor activity of CTX, via immunomodulatory activities such as depletion of Tregs, Th1 cell polarization, and proinflammatory cytokine production, and via apoptotic pathways. IRF-1 may thus serve as a useful predictive biomarker of response to CTX in cancer patients.
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thawed prior of tumor implantation. Cells were grown in RPMI-1640 culture medium, supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 1% glutamine, and were routinely examined for Mycoplasma contamination.
Six-to 8-week-old C57BL/6 and Irf1 2/2 mice were implanted s.c. with 8 3 10 5 RBL-5 tumor cells. CTX (100 mg/kg) (Sigma-Aldrich), or PBS, was administered i.p. 10 days after tumor injection. Some mice were treated also with either the Casp-1 inhibitor VX-765 (InvivoGen, Labogen) dissolved in 25% Cremophor EL or vehicle alone (25% Cremophor EL in water). The inhibitor was administered by 4 daily oral gavages at 80 mg/kg, starting 2 days before and ending 2 days after CTX administration. Tumor growth was monitored twice a week by caliper measurement and reported as mean tumor diameter. Survival was analyzed by the Kaplan-Meier method, using as endpoint the day when the tumors reached a mean diameter of 16 mm or the day of euthanasia. Mice were sacrificed if the tumor was necrotic, if tumor size exceeded 20 mm or if the mice showed signs of distress. The experimental protocols were approved by the Istituto Superiore di Sanit a Review Board.
Real-time PCR
Spleens were stored in RNAlater (Qiagen). Total RNA was purified by TRIZOL reagent (Invitrogen) extraction. cDNA templates were obtained by reverse transcription (Promega), according to manufacturer's instructions. Quantitative real-time PCR amplifications were performed in duplicate with QuantiTect SYBR Green PCR reagents (Qiagen) using an iCycler iQ realtime Thermocycler Detection System (Bio-Rad Laboratories). To verify the amplification of a single product, a melting curve was generated at the end of every run. The relative expression levels were calculated by the comparative cycle threshold (DDC T ) method 43 and were normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression, whose expression is not modulated after CTX. The primers for Gapdh, Irf1, Tbet, Il12p40, Nos2, Casp1, Cxcl10, Il1b, Ifng, Foxp3, Pdl1 and Pdl2 were manually designed and were synthetized by PRIMM (Supporting Information, Table S1 ).
Intracellular cytokine staining and flow cytometry
Spleens were homogenized in the presence of red blood cells lysis buffer (Tris-buffered ammonium chloride) and spleen leukocytes were counted and stratified over Lympholyte-M Gradient (Cederlane) for lymphocyte enrichment. For Treg analyses, cells were first stained with anti-CD4-FITC and anti-CD25-PE (BD-Bioscience). After fixing/permeabilization, cells were incubated with anti-Foxp3-APC according to the manufacturer's instructions (e-Bioscience).
To analyze the percentage of IFN-g producing cells, lymphomonocytes were stimulated overnight with 100 ng/ml PMA and 1 mg/ml ionomycin, in the presence of 1 mg/ml Brefeldin-A and 1 mg/ml Monensin (GolgiPlug, GolgiStop, BD-Bioscience) to prevent cytokine secretion. Following extracellular staining with anti-CD4-FITC, cells were fixed/ permeabilized and incubated with anti-IFN-g-PE-Cy7 (BDBioscience). Acquisition and analysis were performed with FACS Calibur flow cytometer (BD-Bioscience).
Determination of IL-1b, CXCL10 and IL-6 protein levels by ELISA At the indicated time points, plasma was isolated by centrifugation from blood collected in the presence of EDTA and spleens were homogenized in the presence of red blood cell lysis buffer. Subsequently, splenocytes were lysed in T-PER . Samples were centrifuged 10 min at 48C at 15,000 rpm, and the supernatants frozen at 2808C. Total protein concentration was determined with the Bradford Protein Assay (Bio-Rad) and used to normalize the ELISA results.
CXCL10, IL-1b and IL-6 were measured by using Quantikine V R Colorimetric Sandwich ELISA kits (R&D Systems), according to manufacturer's instructions.
Nitrate/nitrite colorimetric assay
Spleens were obtained from WT and Irf1 2/2 mice before and after CTX administration, and were homogenized and stratified over Lympholyte-M Gradient as described. Lymphomonocytes were cultured in DMEM, supplemented with 10% FBS, 1% penicillin-streptomycin, 1% glutamine and 1 mM sodium pyruvate for 3 days and supernatants were frozen. Nitric oxide (NO) levels were evaluated by a colorimetric assay using Griess reagent, according to manufacturer's instructions (Cayman Chemical).
Statistical analysis
Student's t tests were used to calculate differences between the groups. Mouse survival was analyzed by the KaplanMeier method. The survival distributions of treatment groups were compared with the log-rank test. Differences in p values of 0.05 or less were considered significant.
Results

IRF-1 drives the antitumor efficacy of CTX
Our group has previously shown that a single CTX administration (100 mg/Kg) induces a transient regression/stabilization of the lymphoma cell line RBL-5 in C57BL/6 immunocompetent mice. 12 In the same study, it was shown that the effectiveness of CTX was mediated by the immune system of treated mice, as in CTX-treated immunodeficient SCID mice, the effect of CTX was impaired. 12 To evaluate whether IRF-1 plays a direct role in the antitumor efficacy of CTX, WT and Irf1 2/2 mice were inoculated s.c. with RBL-5 tumor cells and treated with CTX ten days after tumor implantation. The administration of CTX in WT mice induced a transient reduction or stabilization of the tumor size, later followed by tumor progression in 70% of mice, and a complete tumor rejection in 30% of animals ( Fig.  1a and 1f) . Conversely, in Irf1-deficient mice, the antitumor effect of CTX was markedly and significantly reduced, as shown by the lack of complete tumor regression in 10 out of 10 CTX-treated Irf1 2/2 mice (100% tumor progression) ( Fig.   1c and 1f) (two-tailed Fisher exact test, p 5 0.019). Moreover, the duration of the transient regression/stabilization by CTX was reduced to a maximum of 6 days in Irf1 2/2 mice as compared to up to 14 days in WT mice ( Fig. 1a and 1c) . The Kaplan-Meier survival analysis indicated that, although CTX treatment significantly increased survival in both WT and Irf1 2/2 mice with respect to untreated mice ( Fig. 1b and 1d ), only in WT tumor-bearing mice, it triggered a complete and long-lasting cancer regression in 30% of mice (Fig. 1b) . Kaplan-Meier survival analysis also showed that the survival of CTX-treated WT mice was significantly longer than that of Irf1 2/2 mice (p 5 0.021) (Fig. 1e) . Noteworthy, the mice but not the tumor cells are Irf1 deficient, suggesting that the different responses of WT and Irf1 2/2 mice to CTX depend on host immune-mediated rather than cancer autonomous mechanisms.
CTX treatment modulates the gene expression of Irf1 in the spleen of tumor-bearing mice
To unravel the host systemic IRF-1-mediated mechanisms driving the antitumor efficacy of CTX, we first analyzed the effect of a single CTX administration on the modulation of . The endpoint used for survival analyses is the day when the tumors reach a mean diameter of 16 mm or the day of euthanasia (n 5 8-11). p values were calculated using the log-rank test. One representative experiment (out of two) is shown. (f) Number and percentage (in parenthesis) of mice showing tumor rejection (or progression) after treatment with CTX or saline (CTR). p values were calculated using the Fisher exact probability test (two-tailed).
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Irf1 gene expression in the spleen of tumor-bearing and tumor-free C57BL/6 mice. As schematically shown in Fig. 2a and 2c, 10 days after RBL-5 tumor cell injection (or in the absence of tumor injection), some mice were treated with CTX. Before (Day 0), and 2 and 7 days after CTX administration, the mice were sacrificed, spleen removed and analyzed for Irf1 gene expression by real-time PCR. Two days after the treatment, a statistically significant increase of Irf1 transcript levels was observed in both tumor-bearing and tumor-free mice, whereas at Day 7, the gene expression returned comparable to that of untreated mice ( Fig. 2b and  2d ). This result suggests that the effect of CTX is early and transient, similar to what we previously observed for most genes modulated by CTX. 12, 13 IRF-1 regulates the depletion of CD4
Foxp3
1 Treg cell induced by CTX Following our previous evidences on the expansion of Th1 and Th17 cells and depletion of Treg cells by CTX, 13 we next determined whether these systemic effects were dependent on IRF-1 by comparing the consequence of a single CTX injection in C57BL/6 WT and Irf1 2/2 tumor-bearing mice. The effect of CTX on the percentages of CD4 Fig. 3a and 3b) , possibly through the peripheral conversion of CD4
1 T cells to Treg cells caused by tumorproduced TGF-b. 44 Unpredictably, in contrast with our previous data on tumorfree mice, 33 the basal levels (Day 0) of Treg cells shown in Fig.  3b appear identical in WT and Irf1 2/2 tumor-bearing mice.
Assuming that the presence of the tumor could have altered the levels of Treg cells with respect to tumor-free mice, we analyzed the difference between the percentages of CD25 (Fig. 3c) . To deepen the molecular mechanism underlying this phenomenon, we analyzed the effect of chemotherapy on Foxp3 gene expression in the spleen of tumor-bearing, CTX-treated WT and Irf1 2/2 mice. Real-time PCR analysis was performed 2 days after the administration of chemotherapy, that is, when the transcriptional modulation of Irf1 was maximal in WT mice (Fig. 2b) , and 7 days after CTX, when Irf1 transcripts returned to baseline levels (Fig. 2b) . In accordance with the CTX-mediated inhibition of Treg cells, WT mice showed a significant (p < 0.01) progressive reduction of Foxp3 mRNA levels following CTX treatment (Fig. 3d) , as compared to untreated mice, while in Irf1-deficient mice Foxp3 transcript levels were stable, indicating that IRF-1 may be involved in the reduction of Foxp3 expression induced by CTX.
Of interest, in line with previous data, 11 CTX administration induced in tumor-bearing WT mice a spleen leukocyte depletion 2 days following treatment and a rebound at Day 8, and these effects were similar in Irf1 2/2 mice ( Supporting  Information, Fig. S1A ). On the other hand, CD4
1 cell percentages underwent an increase 2 and 8 days following CTX in both WT and Irf1 2/2 tumor-bearing mice ( Supporting  Information, Fig. S1B ). These data show that CTX has different effects on different cell populations, in some cases resulting in depletion of a subset and in others in an increase. These results suggest also that neither the CTX-mediated modulations of leukocyte number nor of CD4 1 cell percentage depend on IRF-1, suggesting that the effect of IRF-1 on Treg modulation by CTX is specific and does not reflect a general effect of CTX, but depends on the activity of IRF-1 on one of its target genes.
As the PD-1/PD-L1 pathway plays an important role in inhibiting the antitumor immune response and IRF-1 was shown to regulate the expression of both Pdl1 and Pdl2, 45, 46 the effect of CTX administration on both genes was analyzed. Unexpectedly, in spite of the rise of Irf1 expression 2 days after CTX treatment (Fig. 2) , Pdl1 gene expression significantly decreased 7 days following CTX treatment only in WT 
Tumor Immunology and Microenvironment
treatment, the percentage of CD4
1 T cells that produce IFN-g in Irf1 2/2 mice was lower than that detected in WT mice, as already reported. 31 CTX treatment induced a Th1 cell expansion in WT mice, particularly evident at Day 10, when the percentage of cells producing IFN-g is two times higher than pretreatment levels, while in Irf1 2/2 mice, no significant modulation was observed (Fig. 4a, 4b) . Interestingly, the expansion of IFN-g-producing cells did not interest only CD4 To further analyze the role of IRF-1 in the CTX-induced polarization toward the Th1 phenotype, we evaluated the modulation of the expression of genes typically related to the differentiation of this T cell subset, such as Il12p40, Tbet and Ifng, in spleen cells of tumor-bearing WT and Irf1 2/2 mice at different times after CTX treatment. As shown in Fig. 4c , a statistically significant increase of Il12p40 expression was induced in WT mice already 2 days after CTX administration, as compared to control mice, while for Tbet and Ifng, the observed trend of increase was not significant. On the contrary, in Irf1 2/2 mice, we did not observe any significant modulation of Il12p40 expression, indicating that IRF-1 is involved in the transcriptional modulation of Il12p40 by CTX. Moreover, in Irf1 2/2 the transcript levels of Ifng decreased significantly (p 0.01) 7 days following CTX treatment, differently from WT mice (Fig. 4c) , further stressing the essential role played by IRF-1 in Th1 differentiation.
IRF-1 plays a key role in modulating the sterile inflammatory response induced by CTX
CTX is cytotoxic not only for tumor cells but also for all dividing cells, including leukocytes (Supporting Information, Fig. S1A ). We previously reported that the death of leukocytes induced by CTX is accompanied by the release of danger signals that lead to the induction of a sterile inflammatory response which, in turn, triggers an increased production of cytokines and chemokines a phenomenon acknowledged as "cytokine storm". [11] [12] [13] The expression of some IRF-1-regulated genes, also characteristic of the CTX-induced inflammatory response, such as Nos2, Cxcl10 and Il1b, was thus analyzed in WT mice versus Irf1 2/2 mice after CTX administration. In line with previous data, 13, 16 the administration of CTX induced a significant increase of Nos2 and Cxcl10 gene expression in WT mice (Fig. 5a ). This increase was maximal 2 days after treatment and lasted until Day 7 for Nos2 (Fig.  5a ). In contrast, in Irf1 2/2 mice Nos2 gene expression did not undergo any significant increase 2 days after CTX treatment and at Day 7 significantly declined as compared with untreated mice, indicating that IRF-1 has a direct role in regulating Nos2 expression following CTX. On the contrary, Cxcl10 transcripts were transiently increased at Day 2 and declined at Day 7 with a similar kinetic in both WT and Irf1-deficient mice (Fig. 5a ), suggesting that CTX-mediated stimulation of Cxcl10 transcription is independent from IRF-1. The analysis of the modulation of Il1b gene expression after CTX treatment confirms the already observed reduction of expression in the spleen of WT mice, 12 this reduction did not occur in Irf1 2/2 mice. In parallel, the modulation of NO levels, the product of iNOS enzymatic activity, in the supernatants of in vitro cultured splenic lymphomonocytes (Fig. 5b) , the variation of CXCL10 concentration in plasma (Fig. 5c ) and of IL-1b protein in spleen cell lysates (Fig. 5d) were analyzed in WTtreated and untreated mice. Only the time points where a statistically significant change was observed are shown. Increased in vitro levels of NO and in vivo plasma levels of CXCL10 were observed after treatment with CTX, confirming the mRNA analysis results (Figs. 5b and 5c ). In contrast, the evaluation by ELISA of IL-1b in spleen cell lysates showed that the administration of CTX induced a significant increase of this cytokine already at Day 2 (Fig. 5d) , showing a discrepancy between Il1b mRNA and IL-1b protein regulation by CTX.
The same analyses were performed in CTX-treated and untreated Irf1 2/2 mice, showing a trend toward the increase of CXCL10 and no change of NO and IL-1b levels (data not shown).
CTX modulates inflammation through a mechanism mediated by the IRF-1-target gene CASP-1
We then analyzed the expression of Casp1, a component of the inflammasome that plays a crucial role in the proinflammatory response triggered by damage, by activating IL-1b and IL-18, 38 and is a direct target gene of IRF-1. 39 As shown in Fig. 6a , Casp1 mRNA levels were significantly increased 2 days after CTX administration only in WT mice, indicating that Casp1 is induced by CTX through IRF-1. Based on the above results, we hypothesized that CTX may modulate IL1b by a CASP-1-mediated post-translational mechanism, which may explain the opposite trends of Il1b mRNA and IL-1b protein (Fig. 5) . To verify this hypothesis, we measured the protein concentration of IL-1b in spleen lysates of tumor-bearing WT mice after treatment with CTX alone or co-treatment with CTX and VX-765, a selective inhibitor of CASP-1 activity. Following treatment with CTX alone, a statistically significant increase of IL-1b protein concentration was observed (Fig. 6b) . This increase was completely inhibited by co-treatment with VX765, demonstrating an important role of CASP-1, and thus of IRF-1, in the regulation of IL-1b by CTX in the spleen (Fig. 6b) . IL-1b is involved in the regulation of a cascade of cytokines and chemokines through NF-jB and IRF-1, including IL-6 47 and CXCL10. 37 Consistently with IL-1b modulation following CTX treatment, IL-6 and CXCL10 protein levels were increased in the spleen of tumor-bearing mice and this rise was inhibited by the co-administration of the CASP-1 inhibitor (Fig. 6c) ; therefore, although Cxcl10 gene expression following CTX is independent of IRF-1 direct control (Fig.  5a ), the protein levels of CXCL10 are indirectly regulated by IRF-1 thorough the IRF-1/CASP-1 axis (Fig. 6c) . Interestingly, the treatment with the Casp-1 inhibitor, although altering the CTX-mediated cytokine induction, did not affect the capacity of CTX to delay the tumor growth at Day 2 (Fig. 6d) , showing that the cytokine induction is a necessary but not sufficient mechanism underlying CTX antitumor effect. 
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Discussion
In recent years, much attention has been given to the immune-related mechanisms driving the efficacy of chemotherapy and of the combination of chemotherapy with immunotherapy; nevertheless, the underlying molecular mechanisms have not been elucidated yet.
We have previously suggested that CTX-mediated immunomodulation arises from its DNA damage-associated cytotoxicity, cell cycle arrest and cell homeostasis perturbation not only of tumor cells but also of host highly proliferating cells, such as BM and splenocytes, 4 leading to a systemic sterile inflammatory response which activates both the innate and the adaptive immune response. IRF-1 regulates the transcription of a number of target genes that play essential roles in the development of Th1 32 and Treg cells, 33 in the apoptosis induced by DNA damage 39 and in the activation of proinflammatory responses, 38 thus representing the ideal candidate as regulator of CTX immunomodulation. This study shows for the first time that the administration of CTX increases the expression of Irf1 and that this transcription factor plays a key role in the antitumor efficacy and in several immunomodulatory activities of CTX.
Our data demonstrate that IRF-1 is involved into the preferential depletion of Treg cells and expansion of Th1 cells mediated by CTX. We and others have shown that different CD4
1 T cell subsets undergo a transient depletion following CTX, including Th1 and Treg cells. 13, 18 Nevertheless, in the recovery phase, that is characterized by the homeostatic proliferation of different cell subsets, Th1 are preferentially expanded with respect to Treg. 13 Two mechanisms have been proposed so far: (i) the different response of Th1 and Treg cells to the homeostatic cytokines (IL-7, IL-15) produced during the rebound phase, 13 as a result of the low expression of CD127 (the a chain of the IL-7 receptor) in Treg cells, 48 and (ii) an increased sensitivity to apoptosis of CD4 1 CD25
1 spleen cells from CTX-treated mice. 18 This study suggests an additional mechanism to explain the "selectivity" of CTX, mediated by IRF-1, which acts through the positive control of IL12p40 and the negative regulation of Foxp3 expression.
Exposure of naive T cells to IFN-g has been shown to promote Th1 differentiation, through an IRF-1-mediated upregulation of Il12Rb1 and of both IL-12 subunits (Il12p35 and Il12p40). 49 Our results (Fig. 4) show that following CTX treatment, IRF-1 induces an increased expression of Il12p40 and not of Tbet and Ifng in the spleen of tumor-bearing mice, thus influencing the expansion of Th1 cells. At the same time, the progressive and significant reduction of Foxp3 mRNA levels following CTX treatment did not occur in the absence of IRF-1 (Fig. 3) . The expansion of IFN-g-producing Th1 cells was not accompanied by increased Ifng gene expression. The possible reason for this discrepancy is that FACS analysis was performed after stimulation of spleenderived lymphomonocytes with PMA and ionomycin, thus on activated Th1 cells. On the contrary, the real-time PCR analysis was performed on unstimulated splenocytes, therefore, on resting T cells. Moreover, RNA was not extracted from purified T cells but from the whole spleen, which comprises different cell subsets producing IFN-g, which might not respond to CTX at the same time and at the same extent.
IRF-1 regulates also Pdl1 and Pdl2 gene expression, 45, 46 which are the ligand for PD1. We report here that the expression of Pdl1 and Pdl2 decreased 7 days following CTX administration, in spite of increased Irf1 transcript levels at Day 2. Nonetheless, in the light of the findings by Lee et al. showing that the increase of Pdl1 mRNA and protein upon IFN-g treatment is rapid and is followed by a reduction at later time points, 45 we cannot exclude the possibility that the observed decline (at Day 7) is subsequent to a rise between Day 2 and Day 7 that our time course analysis failed to reveal. Regarding the differential effect of the absence of IRF-1 on Pdl1 and Pdl2 gene expression modulation, it should be noted that while the Pdl1 promoter is solely and strongly regulated by IRF-1, the Pdl2 promoter is weakly bound by IRF-1 and regulated also by STAT3. 46 A pivotal mechanism for the immune-adjuvant activity of CTX is also the activation of a sterile inflammatory response. 4 Taken together the results of Figs. 5 and 6 show that CTX regulates different cytokines by different transcriptional and post-translational mechanisms involving IRF-1. Here we report that CTX stimulates the expression of Nos2 and of Casp1 in an IRF-1-dependent manner, according to literature, 35, 39 while the observed rise of Cxcl10 mRNA following CTX treatment exhibited an IRF-1 independent transcriptional regulation, differently from the report of Harikumar et al. in which Cxcl10 appeared to be under the direct transcriptional control of IRF-1 following IL-1 administration. 37 On the other hand, we show here that the protein levels of CXCL10 are indirectly regulated by IRF-1 thorough the IRF-1/CASP-1 axis (Fig. 6) . Other studies have shown that, in response to IL-1b and IFN-g, the Cxcl10 gene is regulated through NF-jB, 50 which we found upregulated following CTX. 13 It is thus possible to speculate that following CTX administration, the gene expression of Cxcl10 is preferentially regulated by NF-jB rather than by IRF-1. Further studies are needed to confirm this hypothesis. Noticeably, CXCL10 transcription and release is promoted also following anthracyclinebased chemotherapy, whose antitumor effectiveness depends on the induction of anticancer immune responses. 51 Regarding IL-1b, CTX administration induced in the spleen of tumor-bearing mice a reduction of its gene expression (Fig. 5a) , as previously reported, 12 but an increase in the protein levels (Fig. 5d) . This result suggests that a posttranslational mechanism is predominantly implicated in the regulation of IL-1b in the spleen as compared with other tissues such as the bone marrow, where we have previously shown that CTX treatment induces the increase of both IL1b mRNA and protein. 12, 13 DAMP-triggered inflammation can be elicited in response to various noninfectious harmful stimuli including mechanical trauma, ischemia, toxins, crystals, chemicals, dead cells and their debris, 52 and by CTX-killed leukocytes. 4, 13, 16 The recognition of sterile DAMPs, including ATP from dead cells, is mediated by the inflammasome, a multimeric protein complex constituted by a sensor molecule, such as NLRP3, the adaptor protein ASC and CASP-1, 40 which cleaves and activates the precursors of the proinflammatory cytokines IL-1b and IL-18, thus initiating an inflammatory response. A two-step model has been proposed for the inflammasome activation: TNFR and IL-1 R activate NF-jB, leading to the transcription of NLRP3 and pro-IL-1b. The second step is provided by exogenous and endogenous molecules, such as crystalline molecules or ATP, that require phagocytosis and culminates in the activation of CASP-1. 40 Our data provide evidence that CTX regulates Casp1 expression through IRF-1 and that the inhibition of CASP-1 activity disrupts the ability of CTX to increase the protein levels of IL-1b. Our results also suggest that the regulation of CXCL10 and IL-6 in the spleen of CTX-treated mice is mediated by IL-1b, most likely through NF-jB, as reported in 47 and in 50 rather than by a direct IRF-1 control as suggested by Harikumar et al. 37 The increased levels of IL-1b, IL-6 and CXCL10, following CTX administration may, in concert, recruit antigen-presenting cells in inflammatory sites and trigger an acute inflammatory reactions. Nevertheless, the inflammatory response induced by CTX is not sufficient by itself to support the antitumor effectiveness of CTX but necessitates the cooperation of all the different immunomodulatory mechanisms of this drug. 3 In fact, the inhibition of CASP-1, although blocking the stimulation of IL-1b, CXCL10 and IL-6 by CTX, did not block its antitumor effect (Fig. 6) .
It is important to highlight that, although chronic inflammation can be immunosuppressive, signals that trigger acute inflammatory reactions stimulate DC maturation and antigen presentation and therefore an effective anticancer immunity. 53 The inflammasome activation can cause a rapid, proinflammatory form of cell death called pyroptosis. 40 Interestingly, IRF-1 was shown to play a role in controlling CASP-1-dependent pyroptosis and inflammation during LPSinduced acute lung injury in mice. 34 In this respect, CASP-1, regulated by IRF-1, may thus represent the potential link between the death of leukocytes induced by CTX and the inflammatory response. Moreover, previous studies have shown that IRF-1 directly mediates the IFN-g-induced apoptosis via the activation of Casp1 gene expression in ovarian cancer cells. 54 It remains to be established whether the induction of Casp1 by CTX can also drive the apoptosis of leukocytes in addition to inflammation and how IRF-1 can regulate these signals.
A central role has been attributed to IRF-1 and IFNstimulated genes in the so-called "immunologic constant of rejection," a signature upregulated in regressing melanoma metastases after immunotherapy 55 that plays a central role in orchestrating the immune response and generating the switch from chronic to acute inflammation also in several immunemediated tissue destruction processes. 56 A recent paper showed that metastatic melanoma patients have significantly lower Irf1 gene expression in PBMC, which was associated to decreased expression of the cytotoxic molecule perforin and lower levels of IFN-g production and pSTAT-1, pSTAT-4, pSTAT-5 compared with healthy donors, indicating a cancer-associated immunosuppression that may facilitate tumor progression. 57 Overall, the present data indicate that IRF-1, by controlling the expansion of Th1, the inhibition of Treg cells and the systemic inflammatory response, plays a key role in Tumor Immunology and Microenvironment regulating several mechanisms through which an acute administration of CTX reduces the tumor-induced tolerance and shifts the balance toward an effective antitumor immune response. The importance of IRF-1 in contributing to the anticancer efficacy of CTX foresees the analysis of the status of Irf1 (gene expression levels or polymorphisms) in cancer patients' PBMC as a predictive marker for the efficacy of CTX or of its combination with immunotherapy, with the final intent to select patients who can definitely benefit from these therapeutic regimens.
